POZ Community Forums
Meds, Mind, Body & Benefits => Insurance, Benefits Programs & HIV => Topic started by: Billy B on December 17, 2011, 12:59:34 pm
-
Hello Members,
I just wanted to let people know that Truvada & Isentress have assistance programs for individuals with private/group insurance. The Truvada Card can also be used for either of the two meds that are in it. My ID gave me the Truvada Card and the Isentress certificate can be downloaded from their site. My pharmacy accepted these without any problems and now my co pays are covered for a year.
Peace,
Billy
-
Hi Billy,
Thanks so much for sharing this. I don't know if you can change the thread head (I just learned I can change it for my post) , but I believe now ALL of the pharma companies offer co-pay assistance for the insured. There are a couple of places with charts online -- I'll try to find the link. Kaletra, Atripla, and on and on are offering them. I believe David Evans wrote an article some time ago about the programs, too.
I have you to thank for turning me on to the I/T co-pay assistance. I've got my card and coupon ready for the next refill!!! But it also caused me to look into it further since it doesn't seem to be known broadly by those who are insured and figure they're lucky enough to have insurance --- how could they possibly be eligible for assistance.
I'm glad the pharmaceutical companies are doing this and that the FPC made it a priority to negotiate it.
Em
-
Em,
Thanks for the suggestion. As you see I was able to change the title.
Peace,
Billy
-
Hi Billy,
Thanks much -- and peace to you, too!
Em
-
Here is the link to the information for most companies.
http://www.aidsmeds.com/articles/PAPs_Copays_19740.shtml
Peace,
Billy
-
Merck And The ADAP Crisis Task Force Announce New Agreement To Improve Access And Care For People With HIV:
http://www.medicalnewstoday.com/releases/239567.php
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the ADAP Crisis Task Force (ACTF) announced a number of new initiatives to help struggling state AIDS Drug Assistance Programs (ADAPs) continue to provide access to medicines to people living with HIV. This is the third major response from Merck and ACTF in the last four years, as the financial crisis for these critical state programs continues.
Merck has agreed to:
Again lower the price of ISENTRESS® (raltegravir) to eligible ADAPs, effective Jan. 1, 2012. The new price will be "frozen" and will be available as part of the existing Merck special pricing program through Dec. 31, 2013. Merck was the first company to freeze the price of an antiretroviral (ARV) therapy to ADAPs in 2003.
In addition, Merck and ACTF have agreed to the following initiatives:
Increasing support for the Welvista ADAP Program. After its initial year in 2010 and evaluation of current needs, Merck is increasing it operations funding and medication donations for the Welvista ADAP Program. The program helps address the medication needs of ADAP clients who are currently on state ADAP waiting lists by expediting access to HIV medicines through a simplified application process.
Working to optimize the use of comprehensive health insurance options available to persons with HIV. Between 2009 and 2010, the use of private insurance by ADAPs tripled to more than 110,000 persons. The National Alliance of State and Territorial AIDS Directors (NASTAD) reported about 40 ADAPs used ADAP funds to purchase health insurance or pay insurance premiums, co-payments and/or deductibles for individuals eligible for ADAP (provided the insurance has comparable formulary benefits to that of the ADAP). Merck and NASTAD will seek solutions that overcome barriers to more widespread use of such approaches, such as expanding enrollments in Medicare Part D, private insurance and pre-existing condition insurance plans (PCIPs).
ISENTRESS is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adult patients. The label for ISENTRESS is based on analyses of plasma HIV-1 RNA levels through 96 weeks in three double-blind controlled Phase III clinical studies of ISENTRESS. Two of these studies were conducted in clinically advanced, three-class ARV [non-nucleoside reverse transcriptase inhibitor (NNRTI), nucleoside reverse transcriptase inhibitor (NRTI), protease inhibitor (PI)] treatment-experienced adults and one was conducted in treatment-naïve adults. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response. The safety and efficacy of ISENTRESS have not been established in pediatric patients....
-
This is good news. Thanks for posting this!! More help for the uninsured and they are already helping the insured. Thank you Merck -- may others follow suit.
-
anyone know if there is any assistance for the drug called serostim,my innsurance wiill no longer approve it as part of my hiv drug regiment. if any of you guys have any extra ,let me know!!!lol
-
anyone know if there is any assistance for the drug called serostim,my innsurance wiill no longer approve it as part of my hiv drug regiment. if any of you guys have any extra ,let me know!!!lol
Armando,
I found this:
https://www.rxhope.com/pap/info/paplist.aspx?programid=1488&fieldtype=programid
-
What I've found is if you Google whatever your med name is (HIV-related or not) and the words 'co-pay assistance' -- you'll find whatever coupon or assistance options are open to you. That is the other Google-able option -- the med name plus the word 'coupon'